Chris Kirton | Former Head of Cellular Operations

This person is a member of Sanger Institute Alumni.

Kirton, Christopher Michael

Chris Kirton left the Sanger Institute in July 2017. He is now Head of Operations at Absolute Antibody.

Chris Kirton has a background in molecular immunology and biopharmaceutical drug development, mainly antibodies and vaccines. Prior to joining the Sanger Institute Chris was a post-doc in the Division of Immunology at Cambridge University where he developed a monoclonal antibody against the inflammatory mediator VAP-1 and later became Head of the Cell Biology and Biopharmaceutical areas at ENVIGO, a global CRO.


  • Activated platelets adherent to an intact endothelial cell monolayer bind flowing neutrophils and enable them to transfer to the endothelial surface.

    Kirton CM and Nash GB

    The Journal of laboratory and clinical medicine 2000;136;4;303-13

  • Regulation of parietal cell migration by gastrin in the mouse.

    Kirton CM, Wang T and Dockray GJ

    American journal of physiology. Gastrointestinal and liver physiology 2002;283;3;G787-93

  • Gastrin induces proliferation in Barrett's metaplasia through activation of the CCK2 receptor.

    Haigh CR, Attwood SE, Thompson DG, Jankowski JA, Kirton CM et al.

    Gastroenterology 2003;124;3;615-25

  • COOH-terminal 26-amino acid residues of progastrin are sufficient for stimulation of mitosis in murine colonic epithelium in vivo.

    Ottewell PD, Varro A, Dockray GJ, Kirton CM, Watson AJ et al.

    American journal of physiology. Gastrointestinal and liver physiology 2005;288;3;G541-9

  • Function-blocking antibodies to human vascular adhesion protein-1: a potential anti-inflammatory therapy.

    Kirton CM, Laukkanen ML, Nieminen A, Merinen M, Stolen CM et al.

    European journal of immunology 2005;35;11;3119-30

  • PECAM-1 polymorphism affects monocyte adhesion to endothelial cells.

    Goodman RS, Kirton CM, Oostingh GJ, Schön MP, Clark MR et al.

    Transplantation 2008;85;3;471-7

  • In vitro cytokine release assays: reducing the risk of adverse events in man.

    Kirton CM, Gliddon DR, Bannish G, Bembridge GP and Coney LA

    Bioanalysis 2011;3;23;2657-63

  • Low-affinity FcγR interactions can decide the fate of novel human IgG-sensitised red blood cells and platelets.

    Armour KL, Smith CS, Turner CP, Kirton CM, Wilkes AM et al.

    European journal of immunology 2014;44;3;905-14

  • Clearance of human IgG1-sensitised red blood cells in vivo in humans relates to the in vitro properties of antibodies from alternative cell lines.

    Armour KL, Smith CS, Ip NC, Ellison CJ, Kirton CM et al.

    PloS one 2014;9;10;e109463

  • Successful Generation of Human Induced Pluripotent Stem Cell Lines from Blood Samples Held at Room Temperature for up to 48 hr.

    Agu CA, Soares FA, Alderton A, Patel M, Ansari R et al.

    Stem cell reports 2015;5;4;660-71